SUMMARY Nine patients in whom subacute myelo-opticoneuropathy (SMON) was diagnosed with varying degrees of confidence are discussed. The cases were discovered after a retrospective examination of our 
ticity) from Australia (Selby, 1972 (Selby, , 1973 , India (Wadia, 1973) , Switzerland (Kaeser and Wuthrich, 1970) , Sweden (Osterman, 1971) , Singapore (Tay, 1973) , Great Britain (Terry, 1971; Spillane, 1971 Spillane, , 1972 , United States (Kean, 1972) , France (Grenier et al., 1972; Castaigne, et al., 1973), and Holland (Van Beeck and Scholten, 1972) . The disproportionately high prevalence of this disease in Japan has been commented on by the Japanese themselves (Kono, 1971; Tsubaki et al., 1971; Shiraki, 1973) . Tsubaki et al., (1971) were the first to point out that most of their patients had taken clioquinol before the onset of this disease. It soon became accepted, more so in Japan than elsewhere, that SMON was a clinically identifiable entity that could occur as a result of the ingestion of clioquinol.
An opportunity to acquire first hand knowledge of preliminary report was published concerning the possible occurrence of SMON in Bombay (Wadia, 1973) . This paper reports the cumulative data of two searches for cases of SMON, the first retrospective (based on clinical records and covering a five year period), the second prospective (covering a four and a half year period). These efforts resulted in the finding of nine patients considered, on clinical grounds, to be suffering from SMON. The main aim of the surveys was to identify such patients, and to study them in depth with a view to excluding alternative diagnoses.
limbs. He also mentioned 'deep sensory disturbances' and weakness of the lower limbs. We therefore evaluated as possible cases of SMON all patients with persistent distal dysaesthesiae, especially if of ascending pattern and associated with evidence of myelopathy. Physical signs of associated peripheral or optic neuropathy were not considered essential. Although ankle jerks were absent in the majority of Japanese patients, this was not always the case. Their preservation, in our cases, was not held to invalidate a diagnosis of SMON. The first cardinal feature of the Japanese guidelines (namely abdominal disturbances or pain immediately preceding the onset of neurological symptoms) was not considered mandatory for diagnosis. We realised that if we accepted this criterion strictly, no case of SMON would be diagnosed.
After an overall assessment of the natural history, symptoms, and signs, a diagnosis of SMON was made on a descending scale of likelihood, the categories adopted being 'definite SMON', 'probable SMON', and 'compatible with SMON'. Several patients reviewed were deemed not to have SMON, though perhaps affected by a condition resembling it in some respects. The initial appraisal was made on purely clinical grounds, without reference to the question of clioquinol intake. On obtaining a history of clioquinol consumption its relation to the disease was assessed, taking into consideration the amount of drug ingested, the period over which it was taken, and the relationship of this period to the time of onset of symptoms. If the clioquinol intake had exceeded 10 grams and if the temporal relationship was close, it was felt that a diagnosis of clioquinol-induced SMON could not be excluded. The Table summarises the clinical manifestations, the electrophysiological findings, the clioquinol intake, and our overall conclusion regarding the nine patients accepted, with varying degrees of confidence, as suffering from SMON. Two weeks later there was minimal residual weakness of the dorsiflexors and evertors of the feet, with slight hypertonia at the knees. The tendon reflexes were exaggerated except for the ankle jerks, which were absent. Both plantar responses were extensor. The patient complained of distal dysaesthesiae. Pain and tactile sense were impaired below the groins. Vibration and postural sense were diminished distally. Romberg's sign was positive and she could only walk with support.
Routine blood and CSF examinations were normal. The VDRL was negative. Electrodiagnostic examination revealed chronic partial denervation and slight slowing of motor and sensory nerve conduction in the lower limbs. Myelography showed no abnormality. She refused further investigation.
Seen again 18 months later, she had improved somewhat in that she walked without support. The ataxia and dysaesthesiae were still present. The reflexes were unchanged. She had no abdominal symptoms and had not taken further clioquinol.
In the face of other features of the condition, the absence of optic nerve involvement was not considered strong enough evidence, in this patient, to downgrade the rating from 'definite' to 'probable' SMON. There Accepting these nine patients as cases of SMON, analysis ( Table) showed that females predominated (6:3), and that five of the nine patients were above the age of 50 years when first seen. All except P1 were suffering from chronic, distressing, recurrent diarrhoea, flatulence, and abdominal discomfort or pain, often of many years standing. These symptoms were controlled or made tolerable by the frequent consumption of clioquinol and, in some instances, of other drugs. In only one or perhaps two patients were we convinced that there was a specific abdominal disturbance immediately preceding the neurological illness. Dysaesthesiae, usually up to the lower abdomen, were intense and distressing. They persisted distally, in all cases, despite withdrawal of clioquinol (except in patient P4 whose disease was fleeting).
Clinical evidence of posterior and/or lateral column involvement at a thoracolumbar level was present in all cases. Case P6 had only sensory ataxia. One patient (P7) had predominant sensory ataxia of spinal origin. Three patients (Pi, P4,. and P5) had equal involvement of lateral and posterior columns. Four patients (P2, P3, R1, and R2) had greater pyramidal tract involvement. The pyramidal tract disorder was usually evidenced as spasticity, weakness, and exaggerated deep reflexes; the plantar responses were extensor in only four of the seven patients with other evidence of lateral column involvement. Only one patient (P1) was bedridden at the onset. The others were all ambulant. Even patient P1 began walking after clioquinol withdrawal. Surprisingly, peripheral neuropathy (as evidenced by absent ankle jerks, predominantly or restrictedly distal dysaesthesiae, and reduced nerve conduction velocities or distal denervation) was only seen unequivocally on one occasion (P1).
Clioquinol had been taken in varying amounts by all patients. The maximum ingested was 1000 g, taken continuously over a period of three years (P2). Most other patients had taken the drug repeatedly, over months or years. Clioquinol was actually being taken by all patients at the time ofonset of their neurological complaints. No 'latent period' between stopping the drug and the onset of neurological symptoms was seen in any of our patients. Seven patients were deteriorating when we asked them to stop the drug: withdrawal of the drug was followed by arrest or improvement in their neurological condition. In two patients (R1 and R2) the inadvertent resumption of drug intake, admittedly in small doses, had not obviously resulted in deterioration.
In summary, subacute myelopathy was seen in six patients (P3, P4, P6, P7, R1, and R2), opticomyelopathy in two patients (P2 and P5), and myeloneuropathy once (P1 Pallis (1976) stresses the difficulties, and maintains that large series tend to be 'contaminated' with patients suffering from other neurological disorders. Spillane (1971) , Pallis and Lewis (1974) , and Meade (1975) have expressed similar views.
If we accept our nine patients as cases of SMON, the following overall picture emerges. Females, specially elderly females, predominated. Abdominal symptoms (pain, diarrhoea, flatulence, and mucous discharge) are troublesome. This abdominal condition is nonspecific and was unrelated to amoebiasis. The gastroenterological symptomatology was relieved, often rapidly, by short or long courses of clioquinol and at times by other drugs. Abdominal pain or other abdominal symptoms, immediately preceding the nervous symptoms, were only seen once. Dysaesthesiae, often ascending up to the groins or umbilicus (with signs of myelopathy) were complained of in all cases. Pyramidal tract signs were more obvious than ataxia, but both were often seen. Surprisingly, definite peripheral neuropathy was only confirmed once. Optic neuropathy was seen twice. Clioquinol was being ingested in appropriate amounts right up to the day of onset of the neurological condition, unlike what was seen in some of the Japanese cases.
The widely held view, shared by Japanese authors (Kono, 1971; Tsubaki et al., 1971; Shiraki, 1973) , that SMON is rare outside Japan appears to be confirmed by this study. Whereas some 10,000 cases of SMON were reported from Japan over a 15 year period, we have only been able to find nine cases in Bombay, in a little over nine years. If we consider the prospective study alone, we have seen only seven cases of SMON in four and a half years. It would be incorrect to compare the total Japanese experience, collated through a Commission of Inquiry, with the personal experience of an individual observer. Against this it might be mentioned: (a) that a nationwide scrutiny of retrospective data, carried out by a host of physicians, leads to a greater amount of observer bias, perhaps inflating the figures; (b) that no report of a series of cases, or even of single cases of SMON has appeared from India to date, despite common knowledge of the disorder through books and manufacturers' warnings on packages and leaflets. No reports of SMON have appeared from Brazil, Africa, Pakistan, Bangladesh, Thailand, Malaysia, and Indonesia, which between them must contain the bulk of the world's clioquinol-consuming population; (c) that the Japanese literature mentioned outbreaks and endemic pockets of SMON, even before clioquinol had been incriminated as a possible cause. We doubt that obvious clusters of cases, in and around big neurological centres in India, would have been missed, especially after the Japanese experience had been widely publicised. (d (Wadia, 1973 ) take more than '10 to 40 g of clioquinol', the dose deemed sufficient to cause SMON in Japan (Kono, 1971) .
The factor determining this difference in prevalence has not yet been identified. Various conjectures have been made. Shiraki (1973) discusses fully the endogenous and exogenous factors, other than clioquinol, which could have contributed to the aetiology of SMON in Japan.
The possibility of racial or genetic predisposition (based on a presumed specific enzymatic defect in the Japanese leading to greater clioquinol neurotoxicity), has never been supported by any evidence.
No definite case reports of Japanese overseas developing SMON have yet appeared (Meade, 1975 (Holdstock, 1975; Coxon and Pallis, 1976) Meade (1975) and Pallis (1976) have pointed out it may also have been misdiagnosed (or overdiagnosed) in Japan.
How does one diagnose SMON, especially in its incomplete form, in the absence of any specific laboratory tests and without using the fact of clioquinol consumption as a diagnostic criterion? Today, the diagnosis of SMON outside Japan is largely, if not totally, based on an acceptance of the Japanese experience (Osterman, 1971; Selby, 1972) . This results, at times, in the acceptance of patients as cases of SMON (or of their acceptance as cases of clioquinol neurotoxicity), when the neurological picture is far from typical. In such cases, the very fact of clioquinol intake tends to become-probably unconsciously-a diagnostic criterion. This is illustrated in the cases mentioned by Spillane (1971 Spillane ( , 1972 (1971, 1972) . 4. We have come across a patient the cause of whose myelopathy could not be found at the initial examination. He Industry, 1975) , on the grounds that it is an 'essential drug' and a 'household remedy'. However, it should be used with caution as all drugs should be, and more importantly, it should be withdrawn immediately should neurological symptoms develop.
